• Explore /
  • Poster
  • / Follow-up on phase 1 study of AT101, a novel anti-CD19 chimeric antigen receptor cell therapy (CAR-T) in patients with relapsed or refractory (r/r) b-cell non-Hodgkin lymphoma.

Follow-up on phase 1 study of AT101, a novel anti-CD19 chimeric antigen receptor cell therapy (CAR-T) in patients with relapsed or refractory (r/r) b-cell non-Hodgkin lymphoma.

Abstract Video & Slides Poster

Authors

null

Ki Hyun Kim

AbClon Inc., Seoul, South Korea

Ki Hyun Kim , Dok Hyun Yoon , Jae-Cheol Jo , Seong Hyun Jeong , Sung Yong Oh , Hyungwoo Cho , Yoon Seok Choi , Sung-Hyun Kim , Ji Hyun Lee , LeiGuang Cui , Tae-bum Lee , In-Sik Hwang , Young-Ha Lee , Yong-Jun Lee , Yoon Lee , Jong-Hoon Kim , Jong-Seo Lee , Junho Chung

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL

Clinical Trial Registration Number

NCT05338931

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 7035)

DOI

10.1200/JCO.2024.42.16_suppl.7035

Abstract #

7035

Poster Bd #

18

Abstract Disclosures

Similar Posters

First Author: David Jacob Andorsky

First Author: Matthew Steven Davids

First Author: Laurie Helen Sehn

First Author: Michael Roost Clausen